Translation

Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Summary of Consolidated Financial Results for the Six Months Ended June 30, 2023 (Based on Japanese GAAP)

August 10, 2023

Company name:

D.Western Therapeutics Institute, Inc.

Stock exchange listing:

Tokyo

Stock code:

4576

URL https://www.dwti.co.jp

Representative:

President and CEO

Yuichi Hidaka

Inquiries:

Director

Sayako Matsubara

TEL 052-218-8785

Scheduled date to file Quarterly Securities Report:

August 10, 2023

Scheduled date to commence dividend payments:

-

Preparation of supplementary material on quarterly financial results:

Yes

Holding of quarterly financial results meeting:

Yes

(for analysts and institutional investors)

(Amounts less than one million yen are rounded down)

1. Consolidated financial results for the six months ended June 30, 2023 (from January 1, 2023 to June 30, 2023)

(1) Consolidated operating results (cumulative)

Percentages indicate year-on-year changes

Net sales

Operating profit

Ordinary profit

Profit attributable to

owners of parent

Millions of yen

%

Millions of yen

%

Millions of yen

%

Millions of yen

%

Six months ended June 30, 2023

187

(10.6)

(258)

-

(254)

-

(247)

-

Six months ended June 30, 2022

210

4.2

(132)

-

(118)

-

(110)

-

Earnings per share

Diluted earnings per share

Yen

Yen

Six months ended June 30, 2023

(7.89)

-

Six months ended June 30, 2022

(3.76)

-

(2) Consolidated financial position

Total assets

Net assets

Equity ratio

Millions of yen

Millions of yen

%

As of June 30, 2023

2,820

1,820

64.2

As of December 31, 2022

2,956

1,873

62.8

2. Cash dividends

Annual dividends per share

1st quarter-end

2nd quarter-end

3rd quarter-end

Fiscal year-end

Yen

Yen

Yen

Yen

Year ended December 31, 2022

-

0.00

-

0.00

Year ending December 31, 2023

-

0.00

Year ending December 31, 2023 (Forecast)

-

0.00

Total

Yen 0.00

0.00

3. Forecast of consolidated financial results for the year ending December 31, 2023 (from January 1, 2023 to December 31, 2023)

Percentages indicate year-on-year changes

Net sales

Operating profit

Ordinary profit

Profit attributable to

Earnings per share

owners of parent

Millions of yen

%

Millions of yen

%

Millions of yen

%

Millions of yen

%

Yen

Full year

400

(10.7)

(1,400)

-

(1,410)

-

(1,390)

-

(44.60)

1

4. Notes

  1. Changes in significant subsidiaries during the six months ended June 30, 2023 (changes in specified subsidiaries resulting in the change in scope of consolidation):
  2. Application of special accounting methods for preparing quarterly consolidated financial statements:

No

No

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements

Changes in accounting policies due to revisions to accounting standards and other regulations:

No

Changes in accounting policies due to other reasons:

No

Changes in accounting estimates:

No

Restatement of prior period financial statements:

No

(4) Number of issued shares (common shares)

Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2023

31,955,730

shares

As of December 31, 2022

30,871,138

shares

Number of treasury shares at the end of the period

As of June 30, 2023

285

shares

As of December 31, 2022

100

shares

Average number of shares during the period (cumulative from the beginning of the fiscal year)

Six months ended June 30, 2023

31,448,528

shares

Six months ended June 30, 2022

29,378,997

shares

2

Quarterly consolidated financial statements

Consolidated balance sheets

(Thousands of yen)

As of December 31, 2022

As of June 30, 2023

Assets

Current assets

Cash and deposits

2,334,668

2,235,105

Accounts receivable - trade

170,755

102,911

Supplies

79,211

140,920

Other

74,436

61,928

Total current assets

2,659,072

2,540,866

Non-current assets

Property, plant and equipment

10,105

11,236

Intangible assets

Contract-related intangible assets

123,428

102,857

Other

1,101

763

Total intangible assets

124,529

103,620

Investments and other assets

162,668

164,813

Total non-current assets

297,303

279,670

Total assets

2,956,376

2,820,536

Liabilities

Current liabilities

Current portion of long-term borrowings

120,000

60,000

Accounts payable - other

64,210

124,444

Income taxes payable

11,234

10,236

Other

15,762

12,457

Total current liabilities

211,207

207,138

Non-current liabilities

Convertible-bond-type bonds with share acquisition rights

734,693

624,489

Long-term borrowings

113,000

144,000

Other

24,000

24,000

Total non-current liabilities

871,693

792,489

Total liabilities

1,082,900

999,628

Net assets

Shareholders' equity

Share capital

714,244

815,663

Capital surplus

2,772,484

2,873,902

Retained earnings

(1,629,961)

(1,877,945)

Treasury shares

-

(0)

Total shareholders' equity

1,856,767

1,811,620

Accumulated other comprehensive income

Valuation difference on available-for-sale securities

(222)

(31)

Total accumulated other comprehensive income

(222)

(31)

Share acquisition rights

943

736

Non-controlling interests

15,987

8,583

Total net assets

1,873,475

1,820,908

Total liabilities and net assets

2,956,376

2,820,536

3

Consolidated statements of income (cumulative) and consolidated statements of comprehensive income (cumulative)

Consolidated statements of income (cumulative)

(Thousands of yen)

Six months ended

Six months ended

June 30, 2022

June 30, 2023

Net sales

210,034

187,710

Cost of sales

13,126

14,696

Gross profit

196,908

173,014

Selling, general and administrative expenses

Research and development expenses

199,768

294,752

Other

129,507

136,614

Total selling, general and administrative expenses

329,275

431,366

Operating loss

(132,367)

(258,352)

Non-operating income

Interest income

13

6

Foreign exchange gains

32,820

6,275

Other

1,008

11

Total non-operating income

33,841

6,292

Non-operating expenses

Interest expenses

1,710

1,225

Share issuance costs

-

1,007

Commission expenses

13,250

255

Share issuance costs

4,634

-

Other

-

42

Total non-operating expenses

19,595

2,530

Ordinary loss

(118,120)

(254,590)

Loss before income taxes

(118,120)

(254,590)

Income taxes - current

797

797

Total income taxes

797

797

Loss

(118,918)

(255,387)

Loss attributable to non-controlling interests

(8,436)

(7,403)

Loss attributable to owners of parent

(110,481)

(247,983)

4

Consolidated statements of comprehensive income (cumulative)

(Thousands of yen)

Six months ended

Six months ended

June 30, 2022

June 30, 2023

Loss

(118,918)

(255,387)

Other comprehensive income

Valuation difference on available-for-sale securities

(454)

(31)

Total other comprehensive income

(454)

(31)

Comprehensive income

(119,372)

(255,419)

Comprehensive income attributable to

Comprehensive income attributable to owners of parent

(110,936)

(248,015)

Comprehensive income attributable to non-controlling

(8,436)

(7,403)

interests

5

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

D.Western Therapeutics Institute Inc. published this content on 10 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 August 2023 07:22:04 UTC.